37 results about "Viral nonstructural protein" patented technology

The present invention provides a recombinant nucleic acid comprising: a first nucleic acid sequence encoding a 5′ alphavirus replication recognition sequence; at least one second nucleic acid sequence encoding an alphavirus nonstructural protein; at least one alphavirus subgenomic promoter; at least one IRES element; at least one heterologous nucleic acid; and a third nucleic acid encoding a 3′ alphavirus replication recognition sequence. Further provided are methods of making alphavirus particles comprising a recombinant nucleic acid of this invention and methods of using the compositions of this invention. Also provided is a recombinant helper nucleic acid comprising: a first nucleic acid sequence encoding a 5′ alphavirus replication recognition sequence; an alphavirus subgenomic promoter; an IRES element; a second nucleic acid encoding an alphavirus structural protein; and a third nucleic acid encoding a 3′ alphavirus replication recognition sequence.

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

The invention discloses an activity determination buffer solution and an activity determination method of high-throughput Zika virus non-structural protease, wherein the buffer solution consists of the following buffer ingredients: 10-200mM of trihydroxymethyl aminomethane, 0-20mM of sodium chloride, 0-1mM of CHAPS, 0-20mM of galactose and glycerol which is 10-40% of in volume percentage, and the pH value of the buffer solution is at 8.0-9.0. The buffer solution provided by the invention can improve the activity of the protease in a process of detecting the enzymatic activity of Zika viruses, so that the high-throughput Zika virus non-structural protease activity determination method, which makes use of the buffer solution, is more accurate in result, and subsequently an effect of guiding the screening of Zika virus protease activity inhibitors is achieved and the research and development progress of medicines targeted to the Zika viruses is promoted.

The invention provides a foot-and-mouth disease virus non-structural protein 3B dominant epitope deletion-marked strain as well as a preparation method and application thereof, which belong to the technical field of biotechnology and biological products. Foot-and-mouth disease virus non-structural protein 3B dominant epitope deletion marker strain, the foot-and-mouth disease virus obtained by completely missing the dominant epitope on the basis of non-structural protein 3B; GPYAGP to GPAAP mutation, GPYAGP to GPAAP mutation in 3B2, and GPYEGP to GPYEAA mutation in 3B3. The application of the marked virus strain in preparing the foot-and-mouth disease marked vaccine for distinguishing infection and vaccine immunity can meet the purpose of immune prevention and differential diagnosis, and can be used for effective prevention, control and purification of FMD in my country.

The invention discloses a test paper strip for differential diagnosis of foot-and-mouth disease virus-infected animals and vaccine-immunized animals. Three epitope polypeptides on viral non-structural proteins 2B, 2C, and 3B. The artificial antigen prepared by the present invention has the advantages of easy acquisition, stable structure, purity up to 99%, low cost, rapid mass production, etc., which solves the problem of low expression of traditionally expressed proteins, difficulty in ensuring natural spatial structure, difficulty in renaturation, difficulty in The removal of bacterial proteins affects the specificity of the test results and other shortcomings, and also solves the risk of incomplete virus inactivation when using inactivated viruses. The invention also pre-treats the gold-labeled pad, which is more conducive to the gold-labeled pad’s water absorption and the release of gold-labeled protein, effectively solving the slow and incomplete release of gold-labeled protein in the existing test paper, which affects the detection accuracy, sensitivity and issues such as shelf life.

The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a capsid, recombinant virus membrane proteins attached to the capsid and vRNA packaged within said capsid. The vRNA is generated from a DNA sequence encoding a polypeptide capable of specifically binding to a constant region of a nonstructural protein of the virus that is essential for propagation of the virus.

The invention discloses a foot-and-mouth disease virus non-structural protein monoclonal antibody 7D7, a foot-and-mouth disease virus non-structural protein antibody detection kit containing the monoclonal antibody and an application thereof. The antibody detection kit provided by the invention has high sensitivity and can obviously widen the linear range of detection; the detection is not limited by animal species, and is suitable for large-scale screening of foot-and-mouth disease diseases of artiodactyl animals. The vaccine prepared by the conjugate containing the monoclonal antibody 7D7 can remove non-structural proteins, and can avoid the interference of FMDV non-structural protein antibodies after immunizing animals, thereby accurately distinguishing infected animals from immunized animals.